6532:TSEBayCurrent, Inc Analysis
Data as of 2026-06-17 - not real-time
¥5,585.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Baycurrent, Inc. is trading at ¥5,585, which sits below its 20‑day SMA (¥5,747) and well under the 200‑day SMA (¥6,304), indicating short‑term weakness despite a neutral RSI of 49. Fundamentally, the company delivered a 30% revenue growth year‑over‑year, posted a gross margin of 56.6% and an operating margin of 37.1%, and generated a ROE of 35.8%**, underscoring strong profitability. The current price is roughly 28% below the DCF‑derived fair value of ¥7,571 and 22% below the consensus 12‑analyst target median of ¥6,850**, suggesting significant upside. The PE ratio of 22.4 is well under the industry average of 31.2, while the dividend yield of 2.35% with a 40% payout ratio appears sustainable given the robust cash position (¥72.3 bn) and modest debt load. However, volatility is high at 52% over the past 30 days and trading volume is on a downtrend, which could amplify price swings in the near term. The MACD histogram is negative and the signal line is bearish, reinforcing a cautious short‑term stance. Overall, the blend of solid fundamentals, attractive valuation, and a strong dividend makes Baycurrent a compelling buy for medium to long horizons, provided investors can tolerate the near‑term technical softness.
The low beta of 0.59 points to limited market‑wide risk, and the company operates primarily in Japan’s consulting sector, which faces modest regulatory and geographic risks. The upcoming increase in the annual dividend to ¥50 per share and the guidance for FY2027 revenue of ¥190 bn add further confidence. Given the analyst consensus of “strong buy” and the sizable upside potential, the recommendation is to hold off on immediate entry until the price stabilizes near the support level of ¥5,303, then accumulate for the medium‑ and long‑term upside.
The low beta of 0.59 points to limited market‑wide risk, and the company operates primarily in Japan’s consulting sector, which faces modest regulatory and geographic risks. The upcoming increase in the annual dividend to ¥50 per share and the guidance for FY2027 revenue of ¥190 bn add further confidence. Given the analyst consensus of “strong buy” and the sizable upside potential, the recommendation is to hold off on immediate entry until the price stabilizes near the support level of ¥5,303, then accumulate for the medium‑ and long‑term upside.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below short‑term SMA
- Decreasing volume and high 30‑day volatility
- Support level at ¥5,303 offering downside protection
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 30% YoY revenue growth and high operating margins
- Undervalued relative to DCF fair value and industry PE
- Sustainable dividend with payout ratio ~40%
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strong cash generation and low leverage
- Consistent profitability and high ROE
- Analyst consensus of strong‑buy and significant upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth30.30%
Profit Margin25.51%
P/E Ratio22.4
ROE35.79%
ROA22.56%
Debt/Equity5.62
P/B Ratio7.2
Op. Cash Flow¥37.6B
Free Cash Flow¥29.4B
Industry P/E31.2
Technical Analysis
TrendNeutral
RSI49.3
Support¥5,303.00
Resistance¥6,315.00
MA 20¥5,747.45
MA 50¥5,413.10
MA 200¥6,303.99
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value¥7,571.23
Target Price¥7,166.67
Upside/Downside28.32%
GradeUndervalued
TypeGrowth
Dividend Yield2.35%
Risk Assessment
Beta0.59
Volatility52.26%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.